phrykt

Estrella Immunopharma, Inc. (ESLA): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of ESLA were reported in the last 12 months. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

No ESLA insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ESLA short interest

Low short interest. 2.1% of ESLA shares are sold short: about 1 share in 47. Over the last 12 reports the number of shares short went up 887%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 928,945 ESLA shares were sold short, 2.1% of the shares outstanding, up 54.9% from the report before. At the average daily volume of 2.50M shares, buying them all back would take about 1.0 trading days (days to cover).

Shares short, % of all shares

2.14%May 15Oct 302.44%

Days to cover

1.0May 15Oct 305.2

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026928,9452.14%+55%2.50M1.0
Oct 15, 2026599,6471.38%+180%7.57M1.0
Sep 30, 2026214,0300.49%+39%45,9644.7
Sep 15, 2026153,7810.35%+31%36,7964.2
Aug 31, 2026117,1320.27%+91%34,5783.4
Aug 14, 202661,4100.14%+28%23,4472.6
Jul 31, 202648,0540.11%-12%46,0061.0
Jul 15, 202654,4530.13%-39%45,7331.2
Jun 30, 202689,0820.21%-21%36,3692.5
Jun 15, 2026113,3120.27%+37%47,5462.4
May 29, 202682,5990.19%-12%26,9663.1
May 15, 202694,1350.22%-36%35,1972.7

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Estrella Immunopharma company events

Estrella Immunopharma filed 7 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership, listing). The latest was on Oct 29, 2026.

  1. Oct 29, 2026LeadershipThe Board of Directors of Estrella Immunopharma, Inc. appointed Cynthia Pussinen, age 57, as Chief Executive Officer of the Company and as a Class I director and Chairperson of the Board, in each case effective October 25, 2026. Filing
  2. Sep 8, 2026ListingEstrella Immunopharma, Inc. received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that, because the market value of the Company’s listed securities was below $35 million for 30 consecutive business days from July 21, 2026 through August… Filing
  3. Aug 21, 2026ListingEstrella Immunopharma, Inc. received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that, because the closing bid price of the Company’s common stock, par value $0.0001 per share, was below $1.00 per share for 30 consecutive business days… Filing
  4. Jun 30, 2026VoteReported shareholder vote results. Filing
  5. Jan 13, 2026ListingEstrella Immunopharma, Inc. received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that the Company is not in compliance with Nasdaq Listing Rule 5620(a) because the Company has not held an annual meeting of shareholders within the required time period. Filing
  6. Jan 6, 2026AgreementEstrella Immunopharma, Inc. entered into a securities purchase agreement with a healthcare-focused institutional investor, pursuant to which the Company agreed to issue and sell to the Investor (a) in a registered direct offering (i) 4,063,290 shares of common stock, par value $0.0001 per share, of… Filing
  7. Dec 4, 2025AnnouncementEstrella Immunopharma, Inc. issued a press release titled “Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Estrella Immunopharma financials

Famous investors that hold ESLA

2 of the 50 well-known investors we track reported holding ESLA in their latest 13F filing. The largest position is Ken Griffin's, worth $12.9K.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 202627,555$12.9K0.0%New
Jim Simons · Renaissance TechnologiesQ3 202614,700$6.9K0.0%-62%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named ESLA in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Armistice Capital, LLC13G8.4%
Nov 16, 2026Armistice Capital, LLC13G8.4%

Questions about Estrella Immunopharma, Inc. (ESLA) stock

Are ESLA insiders buying or selling?

No ESLA insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in ESLA?

As of Oct 30, 2026, 928,945 ESLA shares were sold short, 2.1% of the shares outstanding, up 54.9% from the report before. At the average daily volume of 2.50M shares, buying them all back would take about 1.0 trading days (days to cover). See the history.

Which famous investors hold ESLA?

2 of the 50 well-known investors we track reported ESLA in their latest 13F filing, including Ken Griffin, Jim Simons. The largest position is worth $12.9K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.